By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...